Evaxion Biotech AS (EVAX)
1.37
-0.03
(-2.14%)
USD |
NASDAQ |
Nov 21, 16:00
1.37
0.00 (0.00%)
Pre-Market: 20:00
Evaxion Biotech Enterprise Value: 3.461M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 3.461M |
| November 20, 2024 | 3.636M |
| November 19, 2024 | 4.574M |
| November 18, 2024 | 4.986M |
| November 15, 2024 | 3.871M |
| November 14, 2024 | 5.279M |
| November 13, 2024 | 5.748M |
| November 12, 2024 | 9.385M |
| November 11, 2024 | 9.62M |
| November 08, 2024 | 10.09M |
| November 07, 2024 | 10.79M |
| November 06, 2024 | 10.50M |
| November 05, 2024 | 10.73M |
| November 04, 2024 | 10.91M |
| November 01, 2024 | 10.62M |
| October 31, 2024 | 11.09M |
| October 30, 2024 | 11.61M |
| October 29, 2024 | 12.49M |
| October 28, 2024 | 12.08M |
| October 25, 2024 | 11.61M |
| October 24, 2024 | 10.97M |
| October 23, 2024 | 10.76M |
| October 22, 2024 | 10.12M |
| October 21, 2024 | 10.01M |
| October 18, 2024 | 10.58M |
| Date | Value |
|---|---|
| October 17, 2024 | 10.99M |
| October 16, 2024 | 10.99M |
| October 15, 2024 | 10.35M |
| October 14, 2024 | 10.87M |
| October 11, 2024 | 10.35M |
| October 10, 2024 | 10.53M |
| October 09, 2024 | 10.81M |
| October 08, 2024 | 11.73M |
| October 07, 2024 | 11.79M |
| October 04, 2024 | 12.36M |
| October 03, 2024 | 12.99M |
| October 02, 2024 | 12.54M |
| October 01, 2024 | 12.25M |
| September 30, 2024 | 13.28M |
| September 27, 2024 | 18.16M |
| September 26, 2024 | 17.82M |
| September 25, 2024 | 16.52M |
| September 24, 2024 | 16.99M |
| September 23, 2024 | 16.88M |
| September 20, 2024 | 17.11M |
| September 19, 2024 | 18.00M |
| September 18, 2024 | 17.83M |
| September 17, 2024 | 17.33M |
| September 16, 2024 | 18.56M |
| September 13, 2024 | 17.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.632M
Minimum
Jun 17 2024
232.76M
Maximum
Nov 04 2021
48.53M
Average
32.96M
Median
Jan 12 2023
Enterprise Value Benchmarks
| Ascendis Pharma AS | 7.511B |
| DBV Technologies SA | 1.221M |
| Adaptimmune Therapeutics PLC | 26.67M |
| Akari Therapeutics PLC | 24.35M |
| Biodexa Pharmaceuticals PLC | -3.355M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.935M |
| Revenue (Quarterly) | 3.017M |
| Total Expenses (Quarterly) | 4.748M |
| EPS Diluted (Quarterly) | -0.40 |
| Profit Margin (Quarterly) | -64.14% |
| Earnings Yield | -204.4% |
| Normalized Earnings Yield | -182.03 |